Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Lotung Poh-Ai Hospital Tomorrow Medical Foundation |
---|---|
Information provided by: | Lotung Poh-Ai Hospital |
ClinicalTrials.gov Identifier: | NCT00729339 |
Gastroesophageal reflux disease (GERD) is a very common disease in the Western World. In Taiwan, this disease is increasing gradually because our eating style is closing to Western world.
Proton pump is the main drug for patients with GERD in the past two decades. Prokinetic agent is an important adjuvant to the therapy of GERD.This study aims to evaluate the role of prokinetic agent in the management of GERD.
Condition | Intervention | Phase |
---|---|---|
Gastroesophageal Reflux Disease |
Drug: mosapride for the first month and placebo for the 2nd month Drug: placebo for the first and mosapride for the second month |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Crossover Assignment, Efficacy Study |
Official Title: | Role of Mosapride in Patients With Gastroesophageal Reflux Disease |
Estimated Enrollment: | 100 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | July 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
lansoprazole plus mosapride for the first month, and followed by lansoprazole plus placebo for the second month
|
Drug: mosapride for the first month and placebo for the 2nd month
lansoprazole 30mg once per day for 2months mosapride 5mg thrice per day, for the first month placebo thrice per day, for the second month
|
2: Active Comparator
lansoprazole plus placebo for the first month, and lansoprazole plus mosapride for the second month
|
Drug: placebo for the first and mosapride for the second month
lansoprazole 30mg once per day for 2months placebo thrice per day, for the first month mosapride 5mg thrice per day, for the second month
|
This is a randomized, double-blind, cross-over study. FSSG is obtained at the beginning, one month and two months of the study.
This study plans to enroll 100 patients with symptoms of GERD (acid regurgitation, belching, dysphagia). After receiving endoscopic examination, a frequent scale for the symptoms of gastroesophageal reflux disease (FSSG) is obtained from these patients. Fifty patients receive lansoprazole 30 mg once plus mosapride 5 mg tid daily in the first month; and lansoprazole 30 mg once plus placebo tid daily in the second month. Another fifty patients receive lansoprazole 30 mg once plus placebo tid daily in the first month; and lansoprazole 30 mg once plus mosapride 5 mg tid daily in the second month.
Ages Eligible for Study: | 18 Years to 90 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Hwai-Jeng Lin, M.D. | 886-3-954-3131 ext 5411 | 909010@mail.pohai.org.tw |
Taiwan | |
Lotung Poh-Ai Hospital | Recruiting |
Lotung Town, Ilan County, Taiwan, 265 | |
Contact: Hwai-Jen Lin, M.D. 886-3-9543131 ext 5411 909010@mail.pohai.org.tw | |
Principal Investigator: Hwai-Jeng Lin, M.D. |
Principal Investigator: | Hwai-Jeng Lin, M.D. | Lotung Poh-Ai Hospital |
Responsible Party: | Lotung Poh-Ai Hospital ( Hsin-Hong Chen/Superintendent ) |
Study ID Numbers: | OMCP-97-011 |
Study First Received: | July 31, 2008 |
Last Updated: | August 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00729339 |
Health Authority: | Taiwan: Department of Health |
Gastroesophageal reflux disease Mosapride Lansoprazole |
Deglutition Disorders Esophageal Motility Disorders Mosapride Digestive System Diseases Esophageal disorder |
Gastrointestinal Diseases Lansoprazole Esophageal Diseases Gastroesophageal Reflux Serotonin |
Serotonin Agonists Neurotransmitter Agents Serotonin Agents Molecular Mechanisms of Pharmacological Action |
Therapeutic Uses Physiological Effects of Drugs Gastrointestinal Agents Pharmacologic Actions |